[go: up one dir, main page]

HRP20150186T1 - Eksendin za lijeäśenje dijabetesa i smanjenje tjelesne težine - Google Patents

Eksendin za lijeäśenje dijabetesa i smanjenje tjelesne težine Download PDF

Info

Publication number
HRP20150186T1
HRP20150186T1 HRP20150186TT HRP20150186T HRP20150186T1 HR P20150186 T1 HRP20150186 T1 HR P20150186T1 HR P20150186T T HRP20150186T T HR P20150186TT HR P20150186 T HRP20150186 T HR P20150186T HR P20150186 T1 HRP20150186 T1 HR P20150186T1
Authority
HR
Croatia
Prior art keywords
exendin
use according
analog agonist
diabetes
preparation
Prior art date
Application number
HRP20150186TT
Other languages
English (en)
Inventor
Mark Fineman
Leigh Macconell
Kristin Taylor
Original Assignee
Amylin Pharmaceuticals, Llc.
Astrazeneca Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20150186(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals, Llc., Astrazeneca Pharmaceuticals Lp filed Critical Amylin Pharmaceuticals, Llc.
Publication of HRP20150186T1 publication Critical patent/HRP20150186T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Peptides Or Proteins (AREA)

Claims (13)

1. Formulacija koja sadrži eksendin i analogni agonist eksendina, biokompatibilni polimer i šećer za uporabu u postupku liječenja dijabetesa kod ljudi, naznačen time, da navedeni postupak obuhvaća: (a) davanje pripravka čovjeku jednom tjedno; i (b) davanje pripravka dovoljnu za održavanje kontinuirane minimalne plazma koncentracije eksendina ili analognog agonista eksendina od oko 170 pg / ml do oko 600 pg / ml u trajanju od najmanje 1 mjeseca.
2. Pripravak za uporabu u skladu s patentnim zahtjevom 1, naznačen time, da je čovjek pretio ili želi ili mu je potrebno smanjiti tjelesnu težinU.
3. Pripravak za uporabu u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time, da je produljena minimalna koncentracija eksendina i analognog agonista eksendina u plazmi oko 170 pg / ml do oko 350 pg / ml.
4. Pripravak za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da je eksendin ili analogni agonist eksendina Eksendin-4.
5. Pripravak za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, da je šećer sukroza.
6. Pripravak za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da se daje jedanput tjedno subkutanom injekcijom.
7. Pripravak za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da je spomenuti dijabetes dijabetes tipa II.
8. Upotreba eksendina ili analognog agonista eksendina za proizvodnju lijeka koji sadrži analogni agonist eksendina, biokompatibilni polimer i šećer za uporabu u postupku liječenja dijabetesa kod ljudi, naznačen time, da spomenuti postupak obuhvaća: (a) davanja lijeka čovjeku jednom tjedno; i (b) davanje lijeka dovoljnog za održavanje kontinuirane minimalne plazma koncentracije eksendina ili analognog agonista eksendina od oko 170 pg / ml do oko 600 pg / ml u trajanju od najmanje 1 mjeseca.
9. Upotreba u skladu s patentnim zahtjevom 8, naznačena time, da je čovjek pretio ili želi ili mu je potrebno smanjiti tjelesnu težinU..
10. Upotreba prema zahtjevu 8 ili zahtjevu 9, naznačena time, da je produljena minimalna koncentracija eksendina i analognog agonista eksendina u plazmi oko 170 pg / ml do oko 350 pg / ml.
11. Uporaba prema bilo kojem od zahtjeva 8 do 10, naznačena time, da je eksendin ili analogni agonist eksendina Eksendin-4.
12. Uporaba u skladu s jednim od patentnih zahtjeva 8 do 11, naznačena time, da se lijek primjenjuje jednom tjedno pomoću subkutanom injekcijom.
13. Uporaba prema bilo kojem od zahtjeva 8 do 12, naznačena time, da je spomenuti dijabetes dijabetes tipa II.
HRP20150186TT 2005-08-19 2006-08-18 Eksendin za lijeäśenje dijabetesa i smanjenje tjelesne težine HRP20150186T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70960405P 2005-08-19 2005-08-19
US77921606P 2006-03-03 2006-03-03
PCT/US2006/032354 WO2007024700A2 (en) 2005-08-19 2006-08-18 Exendin for treating diabetes and reducing body weight
EP06801867.0A EP1971362B1 (en) 2005-08-19 2006-08-18 Exendin for treating diabetes and reducing body weight

Publications (1)

Publication Number Publication Date
HRP20150186T1 true HRP20150186T1 (hr) 2015-05-22

Family

ID=37772212

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150186TT HRP20150186T1 (hr) 2005-08-19 2006-08-18 Eksendin za lijeäśenje dijabetesa i smanjenje tjelesne težine

Country Status (25)

Country Link
US (7) US20090239796A1 (hr)
EP (3) EP3524261B1 (hr)
JP (2) JP5693817B2 (hr)
KR (1) KR101059279B1 (hr)
CN (1) CN105056211A (hr)
AU (2) AU2006283517B2 (hr)
BR (1) BRPI0615358B8 (hr)
CA (1) CA2619426C (hr)
CY (1) CY1122010T1 (hr)
DK (3) DK3524261T5 (hr)
ES (3) ES2968190T3 (hr)
FI (1) FI3524261T3 (hr)
HR (1) HRP20150186T1 (hr)
HU (2) HUE064811T2 (hr)
IL (2) IL189607A (hr)
LT (2) LT3524261T (hr)
MX (1) MX2008002370A (hr)
NZ (2) NZ566763A (hr)
PL (3) PL1971362T3 (hr)
PT (3) PT3524261T (hr)
RS (1) RS53814B1 (hr)
RU (1) RU2421237C2 (hr)
SG (1) SG184730A1 (hr)
SI (3) SI2347762T1 (hr)
WO (1) WO2007024700A2 (hr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2522708C (en) 2003-04-29 2013-05-28 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
PT3524261T (pt) 2005-08-19 2024-01-12 Amylin Pharmaceuticals Llc Exendina para o tratamento da diabetes e redução do peso corporal
CN101453982B (zh) 2006-05-30 2011-05-04 精达制药公司 两件式内部通道渗透递送系统流动调节器
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
PL2157967T3 (pl) 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20110263496A1 (en) 2008-05-21 2011-10-27 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
WO2010028257A1 (en) 2008-09-04 2010-03-11 Amylin Pharmaceuticals, Inc. Sustained release formulations using non-aqueous carriers
PE20120060A1 (es) 2008-10-17 2012-02-23 Sanofi Aventis Deutschland COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN UNA COMBINACION DE INSULINA HUMANA Gly(A21)-Arg(B31)Arg(B32) y DesProexendin-4(1-39)-Lys6-NH2
EP2435061A4 (en) 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
US8682440B2 (en) 2009-08-03 2014-03-25 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
EP2462246B1 (en) 2009-09-28 2017-09-06 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
AU2010317994B2 (en) 2009-11-13 2014-03-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US8759284B2 (en) 2009-12-24 2014-06-24 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
EP2389945A1 (en) * 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
WO2012054817A1 (en) * 2010-10-22 2012-04-26 Mitokine Bioscience, Llc Delaying and/ or treating hyperglycemia, including diabetes, with poly(alkyl carboxylic acids)
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809271B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP2668951B9 (en) 2011-01-25 2017-03-15 Viviabiotech, S.L. 1,2,4-oxadiazole derivatives as drugs modulating the glp-1 peptide receptor
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2729493B1 (en) 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US10865419B2 (en) * 2011-10-24 2020-12-15 The Trustees Of The University Of Pennsylvania Orally administered plastid expressed cholera toxin B subunit-exendin 4 as treatment for type 2 diabetes
RS57727B1 (sr) 2012-03-22 2018-12-31 Novo Nordisk As Kompozicije glp-1 peptida i njihovo dobijanje
TR201903918T4 (tr) 2012-03-22 2019-04-22 Novo Nordisk As Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
PT2858640T (pt) 2012-06-06 2020-06-30 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
MX362190B (es) 2012-12-21 2019-01-08 Sanofi Sa Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon.
WO2014139182A1 (en) 2013-03-15 2014-09-18 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
ES2688462T3 (es) 2013-05-02 2018-11-02 Novo Nordisk A/S Dosificación oral de compuestos de GLP-1
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
PL3139948T3 (pl) * 2014-05-07 2020-08-10 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) * 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016070117A1 (en) 2014-11-02 2016-05-06 Nano Precision Medical, Inc. Implantable medical devices for extended release of therapeutic agents
CR20170314A (es) 2014-12-12 2017-10-20 Sanofi Aventis Deutschland Formulación de relación fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
MX2017012893A (es) * 2015-04-07 2018-01-15 Intercept Pharmaceuticals Inc Composiciones farmaceuticas para terapias combinadas.
SMT202100488T1 (it) 2015-05-22 2021-11-12 Univ Leland Stanford Junior Trattamento dell'ipoglicemia post-bariatrica con exendina(9-39)
KR101661332B1 (ko) * 2015-05-28 2016-09-29 (의료)길의료재단 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US20170098040A1 (en) * 2015-10-06 2017-04-06 Scale Down Weight management system and method
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
EP3468576B1 (en) * 2016-04-15 2023-06-07 Syracuse University Peptide drug improvement using vitamin b12 and haptocorrin binding substrate conjugates
EP3733694A1 (en) 2016-05-16 2020-11-04 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018057977A1 (en) 2016-09-23 2018-03-29 Delpor, Inc. Stable compositions for incretin mimetic compounds
HRP20250278T1 (hr) 2016-11-21 2025-04-25 Amylyx Pharmaceuticals, Inc. Puferovane formulacije eksendina (9-39)
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
WO2018136505A1 (en) * 2017-01-17 2018-07-26 Wayne State University Zwitterionic polymer-insulin compositions and related methods
WO2018165462A1 (en) 2017-03-08 2018-09-13 Intarcia Therapeutics, Inc Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
WO2018191599A1 (en) * 2017-04-14 2018-10-18 University Of Massachusetts Brown fat-selective adipokines
AU2017414006B2 (en) 2017-05-11 2023-07-06 Shenzhen Hightide Biopharmaceutical, Ltd. Use of polypeptide compound in treatment of acute pancreatitis
CN118873634A (zh) 2018-02-02 2024-11-01 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
WO2019240755A1 (en) * 2018-06-11 2019-12-19 Wellesley Pharmaceuticals, Llc Pharmaceutical compositions and methods for weight loss
AU2019359364A1 (en) * 2018-10-12 2021-05-20 Miraki Innovation Think Tank Llc Cold solution for fat reduction
KR102786259B1 (ko) * 2018-10-30 2025-03-26 지아닝 리우 Glp-1 수용체 작용제 활성을 갖는 glp-1 폴리펩티드 및 그의 용도
WO2021214023A1 (en) 2020-04-22 2021-10-28 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
KR102556528B1 (ko) * 2020-12-08 2023-07-17 경희대학교 산학협력단 대사성 질환 예방, 개선 또는 치료용 조성물
CN119770624B (zh) * 2025-03-13 2025-07-08 上海水大技术转移有限公司 一种抗冻蛋白在减肥降糖中的应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US386998A (en) 1888-07-31 Boiler
US3490597A (en) 1966-07-22 1970-01-20 Purolator Products Inc Cover plate for spin-on-filter
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5445781A (en) 1991-08-28 1995-08-29 Centro Sviluppo Settori Impiego S.R.L. Process for the injection molding of non-precatalyzed polymerizable resins at high-pressure and flow
US5509305A (en) 1992-02-12 1996-04-23 Daniel Industries, Inc. Closely coupled, dual turbine volumetric flow meter
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
GB2282891B (en) 1993-10-13 1997-09-03 Tokai Rika Co Ltd Acceleration detecting apparatus
AU684324B2 (en) 1993-11-19 1997-12-11 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP0966297B2 (en) 1996-08-08 2013-02-27 Amylin Pharmaceuticals, Inc. Regulation of gastrointestinal motility
EP1629849B2 (en) * 1997-01-07 2017-10-04 Amylin Pharmaceuticals, LLC Pharmaceutical compositions comprising exendins and agonists thereof
EP1512395A1 (en) 1997-07-18 2005-03-09 Azopax Therapeutics LLC Biodegradable macromers for the controlled release of biologically active substances
WO2000041546A2 (en) * 1999-01-14 2000-07-20 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof
DK1143989T3 (da) 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendiner til glucagonundertrykkelse
US20030087820A1 (en) * 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
NZ514916A (en) * 1999-04-30 2004-06-25 Amylin Pharmaceuticals Inc Exendins and exendin agonists linked to polyethylene glycol polymers
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6162260A (en) 1999-05-24 2000-12-19 Novo Nordisk Biochem North America, Inc. Single-bath biopreparation and dyeing of textiles
ATE275967T1 (de) 2000-01-10 2004-10-15 Amylin Pharmaceuticals Inc Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
US6602997B2 (en) 2000-04-27 2003-08-05 Shin-Etsu Bio, Inc. Whole cell and cell-debris polysaccharide
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
CN1501809B (zh) 2000-12-13 2012-10-10 伊莱利利公司 应用胰高血糖素样促胰岛肽的长期治疗方案
US6819912B2 (en) 2001-11-05 2004-11-16 Freescale Semiconductor, Inc. Variable frequency switching amplifier and method therefor
US7092459B2 (en) 2001-11-08 2006-08-15 Qualcomm, Incorporated Frequency tracking using pilot and non-pilot symbols
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
WO2004036186A2 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
CA2501298A1 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
WO2005040195A2 (en) 2003-10-24 2005-05-06 Azopax Therapeutics Llc Formulation of exendins
WO2005041873A2 (en) * 2003-10-24 2005-05-12 Azopax Therapeutics Llc Formulation of exendin-4
WO2005058252A2 (en) 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
PT1734971E (pt) * 2004-04-15 2012-02-02 Amylin Pharmaceuticals Inc Dispositivo de libertação sustentada baseado em polímero
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
NZ597499A (en) 2004-05-14 2013-04-26 Emisphere Tech Inc Compounds and compositions for delivering active agents
PL1765310T3 (pl) 2004-05-28 2016-04-29 Oryxe Mieszanina do podawania przezskórnego nisko- i wysokocząsteczkowych związków
ATE424848T1 (de) 2004-08-12 2009-03-15 Quest Pharmaceutical Services Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
US20060034889A1 (en) 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
PT3524261T (pt) 2005-08-19 2024-01-12 Amylin Pharmaceuticals Llc Exendina para o tratamento da diabetes e redução do peso corporal
WO2007022518A2 (en) 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
US7512298B2 (en) 2006-12-01 2009-03-31 3M Innovative Properties Company Optical sensing methods
IT1402944B1 (it) 2010-12-15 2013-09-27 Sarong Spa Capsula per bevande e relativa macchina per utilizzare detta capsula
US11638099B2 (en) 2011-12-23 2023-04-25 Shenzhen Shokz Co., Ltd. Bone conduction speaker and compound vibration device thereof
JP6226510B2 (ja) 2012-01-27 2017-11-08 キヤノン株式会社 画像処理システム、処理方法及びプログラム
ITMI20130325A1 (it) 2013-03-05 2014-09-06 Telecom Italia Spa Metodo per misurare e monitorare il livello di accesso a dati personali generati da risorse di un dispositivo d'utente
US9816387B2 (en) 2014-09-09 2017-11-14 United Technologies Corporation Attachment faces for clamped turbine stator of a gas turbine engine
CA2914090C (en) 2015-03-31 2023-08-01 Allen-Vanguard Corporation Frequency and time domain streaming receiver
US9714199B2 (en) 2015-09-17 2017-07-25 I P Creations Limited Concealed amalgamated explosive neutralizer and method of manufacture

Also Published As

Publication number Publication date
SI3524261T1 (sl) 2024-02-29
EP2347762B1 (en) 2019-05-08
ES2526463T3 (es) 2015-01-12
PT1971362E (pt) 2015-02-10
DK1971362T3 (en) 2015-01-26
CN105056211A (zh) 2015-11-18
PL2347762T3 (pl) 2019-09-30
NZ566763A (en) 2011-06-30
US8906851B2 (en) 2014-12-09
IL243317A0 (en) 2016-02-29
AU2011200663A1 (en) 2011-03-10
WO2007024700A2 (en) 2007-03-01
SI2347762T1 (sl) 2019-09-30
PT2347762T (pt) 2019-06-17
KR101059279B1 (ko) 2011-08-24
CA2619426A1 (en) 2007-03-01
MX2008002370A (es) 2008-04-29
US20150150948A1 (en) 2015-06-04
EP1971362B1 (en) 2014-12-03
JP5980872B2 (ja) 2016-08-31
EP3524261A1 (en) 2019-08-14
HUE064811T2 (hu) 2024-04-28
CY1122010T1 (el) 2020-10-14
ES2968190T3 (es) 2024-05-08
NZ593461A (en) 2013-01-25
US20160271225A1 (en) 2016-09-22
DK2347762T3 (da) 2019-06-11
AU2011200663B2 (en) 2013-02-28
BRPI0615358A2 (pt) 2011-05-17
WO2007024700A8 (en) 2007-12-27
US20090239796A1 (en) 2009-09-24
DK3524261T5 (da) 2024-09-02
ES2736184T3 (es) 2019-12-26
AU2006283517A1 (en) 2007-03-01
KR20080038411A (ko) 2008-05-06
DK3524261T3 (da) 2024-01-15
EP3524261B1 (en) 2023-12-13
PT3524261T (pt) 2024-01-12
BRPI0615358B1 (pt) 2019-03-26
RU2008110504A (ru) 2009-09-27
SG184730A1 (en) 2012-10-30
JP2015044831A (ja) 2015-03-12
SI1971362T1 (sl) 2015-03-31
US8329648B2 (en) 2012-12-11
HUE045165T2 (hu) 2019-12-30
JP2009504775A (ja) 2009-02-05
LT2347762T (lt) 2019-08-26
RS53814B1 (en) 2015-06-30
US20130172243A1 (en) 2013-07-04
US20200222509A1 (en) 2020-07-16
US20110245162A1 (en) 2011-10-06
EP2347762A1 (en) 2011-07-27
CA2619426C (en) 2016-06-21
EP1971362A2 (en) 2008-09-24
RU2421237C2 (ru) 2011-06-20
FI3524261T3 (fi) 2024-01-11
PL1971362T3 (pl) 2015-05-29
LT3524261T (lt) 2024-04-10
WO2007024700A3 (en) 2007-08-09
US20180333468A1 (en) 2018-11-22
BRPI0615358B8 (pt) 2021-05-25
US9884092B2 (en) 2018-02-06
IL189607A (en) 2016-10-31
AU2006283517B2 (en) 2010-12-02
JP5693817B2 (ja) 2015-04-01
IL189607A0 (en) 2008-06-05
PL3524261T3 (pl) 2024-04-15

Similar Documents

Publication Publication Date Title
HRP20150186T1 (hr) Eksendin za lijeäśenje dijabetesa i smanjenje tjelesne težine
Malone et al. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy
George et al. Current treatment options for type 2 diabetes mellitus in youth: today’s realities and lessons from the TODAY study
HRP20171894T1 (hr) Kombinacija inzulina i agonista glp-1
Rolla Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety
JP6438944B2 (ja) インスリングラルギン／リキシセナチド固定比率製剤
CN105188736A (zh) 胰岛素给药方案
Oh et al. Efficacy and safety of voglibose plus metformin in patients with type 2 diabetes mellitus: a randomized controlled trial
Crasto et al. New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes
Hoogma et al. Quality of life and metabolic control in patients with diabetes mellitus type 1 treated by continuous subcutaneous insulin infusion or multiple daily insulin injections
Cefalu Evaluation of alternative strategies for optimizing glycemia: progress to date
Hahr et al. Optimizing insulin therapy in patients with type 1 and type 2 diabetes mellitus: optimal dosing and timing in the outpatient setting
Danne Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus
Samad et al. Effect of Withania coagulans and liraglutide on serum Glp-1, postprandial and fasting blood glucose in streptozotocin induced diabetic rats
Edelman Optimizing diabetes treatment using an amylin analogue
UA129418C2 (uk) Композиції, які містять аналог інкретину, та їх застосування
Mesa New insulin types in type 1 diabetes mellitus
US8637096B2 (en) Compositions and method for enhancing insulin activity
Cypryk et al. New faster-acting insulin Fiasp®—do we need a new meal-time insulin?
Radenković et al. Continuous subcutaneous insulin infusion vs. multiple daily injections
Mikhail Insulin U-500, the Practical Solution for the treatment of patients with high insulin requirements
DE602004025040D1 (de) Den blutzuckerspiegel bei diabetes mellitus regulierendes tetrapeptid
Torres Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research
Garg et al. Achieving goal glycosylated hemoglobin levels in type 2 diabetes mellitus: practical strategies for success with insulin therapy
MX2021014997A (es) Agente de vanadio y metformina como principio activo para el tratamiento de padecimientos relacionados con la resistencia a la insulina.